Key Proteo, Inc.
Changing the Clinical Course of Treatable Rare Genetic Disorders
Changing the Clinical Course of Treatable Rare Genetic Disorders
Key Proteo is a pioneering proteomics startup with the mission of democratizing the early detection of rare yet treatable genetic disorders. The company's focus lies in identifying extremely low abundance protein biomarkers that were previously undetectable, with an initial emphasis on the early detection of treatable rare genetic disorders in newborns. Through novel and accessible proteomic analysis, Key Proteo aims to enable early intervention and ultimately change the clinical course for patients and their families afflicted by these disorders. Founded in 2019 and headquartered in the United States, Key Proteo recently received a noteworthy $3.03M Venture Round investment on 16 May 2023. This injection of funding signifies a vote of confidence in the company's potentially life-saving mission and its innovative approach to addressing a critical healthcare need.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $3.03M | - | 16 May 2023 | |
| Seed Round | Unknown | 1 |
|
01 Dec 2021 |
No recent news or press coverage available for Key Proteo, Inc..
We care about your data, and we'd love to use cookies make your experience better.
